EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prognostic Value of Skeletal Muscle Loss in Unresectable Hepatocellular Carcinoma Treated with TACE-Based Combination Therapy

Ningjing Yang, Kaiyu Chen, Chongming Zheng iD, Puchuang Xu iD, Junhao Pan, Yuepeng Jin iD, Gang Chen, Wenhao Hu

Journal of Clinical Medicine · 07.07.2026 · 15 (13) · 5315

DOI: 10.3390/jcm15135315 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 07.07.2026. Verfasst von Ningjing Yang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Foundation of National Health Commission of China-Major Medical and Health Technology Project for Zhejiang Province, Research Foundation of National Health Commission of China–Major Medical and Health Technology Project for Zhejiang Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Decreases in skeletal muscle mass affect the efficacy of and tumor response to various therapies for hepatocellular carcinoma (HCC). This study aimed to investigate the relationship between changes in skeletal muscle mass during TACE-based combination therapy and tumor response and prognosis.

Methods

This retrospective study analyzed 306 patients with unresectable HCC, divided into four groups according to the treatment received: TACE alone (n = 133), TACE plus targeted and immunotherapy combination (TACE + T + I, n = 68), TACE plus immunotherapy (TACE + I, n = 52), and TACE plus targeted therapy (TACE + T, n = 53). Skeletal muscle mass was assessed at the third lumbar vertebral level (L3) before treatment and at six months post-treatment using computed tomography (CT) scans. Patients were stratified based on changes in skeletal muscle index (SMI) values. Kaplan–Meier and Cox proportional hazards models were used to compare overall survival (OS) among groups classified by changes in SMI, while tumor response was assessed with univariate and multivariate analyses, using logistic regression analysis.

Result

A total of 306 patients with unresectable HCC were included in this study. The median OS was 17.0 (0.9–83.0) months in the decreased-SMI group compared with 35.0 (2.0–113.0) months in the non-decreased-SMI group. The overall response rate (CR + PR) was 34.7% in the decreased-SMI group and 53.8% in the non-decreased group. Among different treatment regimens, significant differences in Kaplan–Meier survival curves were observed between the TACE and TACE + T + I groups. In multivariate analysis, decreased SMI remained an independent predictor of poor OS and tumor non-response, whereas a low-SMI pre-treatment was not an independent prognostic factor. Additionally, inadequate nutritional status and compromised liver function were associated with a greater decrease in SMI during comprehensive treatment.

Conclusions

A decline in skeletal muscle index (SMI) among patients with unresectable hepatocellular carcinoma (HCC) undergoing TACE-based comprehensive treatment is associated with poor prognosis and unfavorable tumor response and is further linked to deteriorating nutritional status and impaired liver function. Monitoring SMI provides an effective approach for assessing overall patient condition and predicting clinical outcomes.

Schlagwörter

Stichwörter der Autor:innen

combination therapyhepatocellular carcinomaprognosissarcopeniaskeletal muscle losstransarterial chemoembolization

Autor:innen und Institutionen

  • Department of Radiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China.
  • Department of Hepatobiliary Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China.
  • Zhejiang-Germany Interdisciplinary Joint Laboratory of Hepatobiliary-Pancreatic Tumor and Bioengineering, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325035, China.
  • National Health Commission Key Laboratory of Clinical Nutrition and Intervention, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325035, China.
  • Department of Interventional Radiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China.

ORCID-Profile: Chongming Zheng, Puchuang Xu, Yuepeng Jin

Förderung

  • Research Foundation of National Health Commission of China-Major Medical and Health Technology Project for Zhejiang Province
  • Research Foundation of National Health Commission of China–Major Medical and Health Technology Project for Zhejiang Province

Zitieren

APA

Yang, N., Chen, K., Zheng, C., Xu, P., Pan, J., Jin, Y., Chen, G., & Hu, W. (2026). Prognostic Value of Skeletal Muscle Loss in Unresectable Hepatocellular Carcinoma Treated with TACE-Based Combination Therapy. Journal of Clinical Medicine, 15(13), 5315. https://doi.org/10.3390/jcm15135315

Vancouver

Yang N, Chen K, Zheng C, Xu P, Pan J, Jin Y, et al. Prognostic Value of Skeletal Muscle Loss in Unresectable Hepatocellular Carcinoma Treated with TACE-Based Combination Therapy. Journal of Clinical Medicine. 2026;15(13):5315. doi:10.3390/jcm15135315

BibTeX
@article{Yang2026,
  author = {Yang, Ningjing and Chen, Kaiyu and Zheng, Chongming and Xu, Puchuang and Pan, Junhao and Jin, Yuepeng and Chen, Gang and Hu, Wenhao},
  title = {Prognostic Value of Skeletal Muscle Loss in Unresectable Hepatocellular Carcinoma Treated with TACE-Based Combination Therapy},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {13},
  pages = {5315},
  doi = {10.3390/jcm15135315}
}
Kostenlos starten →